LOCAL ADMINISTRATION OF TRANEXAMIC ACID IN PRIMARY CEMENTLESS TOTAL HIP ARTHROPLASTY: A PROSPECTIVE CONTROLLED CLINICAL STUDY
Abstract
Introduction: Perioperative blood loss and allogeneic transfusion remain important concerns in total hip arthroplasty. This study evaluated whether local intraoperative tranexamic acid reduces postoperative blood loss and transfusion requirements in primary cementless total hip arthroplasty.
Material and Methods: In this prospective, single-center controlled study, 20 adults with hip osteoarthritis undergoing primary cementless total hip arthroplasty were allocated consecutively by an alternating method to an intervention group or control group (10 patients each). The intervention group received 2 g of tranexamic acid diluted in 60 mL of normal saline and administered locally in three 20-mL applications. Hematological parameters, postoperative drainage, and packed red blood cell transfusion requirements were recorded.
Results: On postoperative day 5, mean hemoglobin was 112.3 g/L in the intervention group and 94.4 g/L in the control group (p=0.011), while mean hematocrit was 0.33 and 0.27, respectively (p=0.007). Mean drainage volume on the day of surgery was 239.5 mL versus 520.3 mL (p=0.002), and total drainage was 430.9 mL versus 755.4 mL (p=0.004). Two packed red blood cell units were transfused in the intervention group and 10 in the control group.
Conclusion: Local intraoperative tranexamic acid was associated with higher postoperative hemoglobin and hematocrit values, lower measured drainage volume, and fewer transfused units. Interpretation of drainage outcomes is limited by different drain-activation protocols between groups.
References
2.Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip replacement. Lancet. 2007;370(9597):1508-1519. doi:10.1016/S0140-6736(07)60457-7.
3.Vuille-Lessard E, Boudreault D, Girard F, Ruel M, Chagnon M, Hardy JF. Red blood cell transfusion practice in elective orthopedic surgery: a multicenter cohort study. Transfusion. 2010;50(10):2117-2124. doi:10.1111/j.1537-2995.2010.02697.x.
4.Hays MB, Mayfield JF. Total blood loss in major joint arthroplasty: a comparison of cemented and noncemented hip and knee operations. J Arthroplasty. 1988;3 Suppl. doi:10.1016/S0883-5403(88)80008-1.
5.Sehat KR, Evans RL, Newman JH. Hidden blood loss following hip and knee arthroplasty: correct management of blood loss should take hidden loss into account. J Bone Joint Surg Br. 2004;86(4):561-565.
6.Billote DB, Glisson SN, Green D, Wixson RL. A prospective, randomized study of preoperative autologous donation for hip replacement surgery. J Bone Joint Surg Am. 2002;84(8):1299-1304. doi:10.2106/00004623-200208000-00002.
7.Charrois O, Kahwaji A, Vastel L, Rosencher N, Courpied JP. Blood loss in total hip arthroplasty for rapidly destructive coxarthrosis. Int Orthop. 2001;25(1):22-24. doi:10.1007/s002640000210.
8.Stanworth SJ, Cockburn HA, Boralessa H, Contreras M. Which groups of patients are transfused? A study of red cell usage in London and southeast England. Vox Sang. 2002;83(4):352-357. doi:10.1046/j.1423-0410.2002.00237.x.
9.Jans O, Kehlet H, Hussain Z, Johansson PI. Transfusion practice in hip arthroplasty-a nationwide study. Vox Sang. 2011;100(4):374-380. doi:10.1111/j.1423-0410.2010.01428.x.
10.Browne JA, Adib F, Brown TE, Novicoff WM. Transfusion rates are increasing following total hip arthroplasty: risk factors and outcomes. J Arthroplasty. 2013;28(8 Suppl):34-37. doi:10.1016/j.arth.2013.03.035.
11.Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth. 2004;8(4):267-281. doi:10.1177/108925320400800402.
12.Rawn J. The silent risks of blood transfusion. Curr Opin Anaesthesiol. 2008;21(5):664-668. doi:10.1097/ACO.0b013e32830f1fd1.
13.Taneja A, El-Bakoury A, Khong H, Railton P, Sharma R, Johnston KD, Puloski S, Smith C, Powell J. Association between allogeneic blood transfusion and wound infection after total hip or knee arthroplasty: a retrospective case-control study. J Bone Jt Infect. 2019;4(2):99-105. doi:10.7150/jbji.30636.
14.Juraj M, Jaroslav V, Gazova A, Zufkova V, Kyselovic J, Steno B. Evaluation of efficacy and safety of systemic and topical intra-articular administration of tranexamic acid in primary unilateral total hip arthroplasty. Medicine (Baltimore). 2021;100(26). doi:10.1097/MD.0000000000026565.
15.Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol). 1980;14:41-47.
16.Cai J, Ribkoff J, Olson S, Raghunathan V, Al-Samkari H, DeLoughery TG, Shatzel JJ. The many roles of tranexamic acid: an overview of the clinical indications for TXA in medical and surgical patients. Eur J Haematol. 2020;104(2):79-87. doi:10.1111/ejh.13348.
17.Ueno M, Sonohata M, Fukumori N, Kawano S, Kitajima M, Mawatari M. Comparison between topical and intravenous administration of tranexamic acid in primary total hip arthroplasty. J Orthop Sci. 2016;21(1):44-47. doi:10.1016/j.jos.2015.10.011.
18.Wei W, Wei B. Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty. J Arthroplasty. 2014;29(11):2113-2116. doi:10.1016/j.arth.2014.07.019.
19.Ekback G, Axelsson K, Ryttberg L, Edlund B, Kjellberg J, Weckstrom J, Carlsson O, Schott U. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg. 2000;91(5):1124-1130. doi:10.1213/00000539-200011000-00014.
20.Gilbody J, Dhotar HS, Perruccio AV, Davey JR. Topical tranexamic acid reduces transfusion rates in total hip and knee arthroplasty. J Arthroplasty. 2014;29(4):681-684. doi:10.1016/j.arth.2013.09.005.
21.Alshryda S, Mason J, Sarda P, Nargol A, Cooke N, Ahmad H, Tang S, Logishetty R, Vaghela M, McPartlin L, Hungin APS. Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H). J Bone Joint Surg Am. 2013;95(21):1969-1974. doi:10.2106/JBJS.L.00908.